Table 1.
Characteristics of patients who had both 18F-labelled fluorodeoxyglucose positron emission tomography/computed tomography and prostate magnetic resonance imaging studies
| Age (yr) | MRI before or after PET/CT? | 18F-FDG PET/CT indication | Prostate SUVmax | Prostate MRI indication | MRI result | PSA (ng/mL) | Biopsy result |
| 73 | 2 mo before | Bone metastases (prostate primary) | 3.4 | Negative TRUS biopsy | T2aNxMx | 20.8 | Gleason 4 + 5 = 9 |
| 72 | 11 mo after | Non-Hodgkin lymphoma | 2.7 | Elevated PSA, negative TRUS biopsy | T2aNxMx | 8.8 | Gleason 5 + 3 = 8 |
| 62 | 3 mo after | Cancer of unknown primary | 3.9 | Prostate cancer staging | T3bNxMx | 37 | Gleason 4 + 3 = 7 |
| 75 | 46 mo after | Head and neck cancer | 3.4 | Active surveillance | T1NxMx | 2.28 | Gleason 4 + 3 = 7 |
| 76 | 6 mo before | Gastrointestinal stromal tumour | 3 | Elevated PSA, negative TRUS biopsy | T2bNxMx | 150 | Gleason 3 + 4 = 7 |
| 79 | 22 mo after | Non-Hodgkin lymphoma | 2.9 | Elevated PSA | T2aNxMx | 5.4 | Gleason 3 + 4 = 7 |
| 66 | 30 mo after | Non-Hodgkin lymphoma | 3.1 | Active surveillance | T2cNxMx | 4.8 | Gleason 3 + 4 = 7 |
| 73 | 26 mo after | Oesophageal cancer | 2.4 | Active surveillance | T2cNxMx | 7.8 | Gleason 3 + 3 = 6 |
| 68 | 18 mo after | Cancer of unknown primary | 3.9 | Elevated PSA | T2aNxMx | 6.1 | Gleason 3 + 3 = 6 |
| 74 | 5 mo before | Oesophageal cancer | 3.9 | Elevated PSA | T1NxMx | 7.3 | Gleason 3 + 3 = 6 |
| 68 | 5 mo before | Hodgkin lymphoma | 9.9 | Elevated PSA, negative biopsy | No focus of tumour | 4.7 | High-grade PIN |
| 65 | 39 mo before | Colorectal cancer | 5.2 | Elevated PSA, negative TRUS biopsy | No focus of tumour | 8.6 | High-grade PIN |
| 76 | 34 mo before | Non-Hodgkin lymphoma | 4.2 | Elevated PSA | Suspicious foci bilaterally | 15 | Benign |
| 67 | 4 mo before | Non-Hodgkin lymphoma | 4.1 | Incidental prostatic 18F-FDG uptake | Suspicious foci bilaterally | 5.5 | Benign |
| 72 | 16 mo after | Pyrexia of unknown origin | 2.7 | Chronic urinary infection | Likely prostatitis | Not done | Biopsy not performed |
| 78 | 1 mo after | Non-Hodgkin lymphoma | 3.1 | Elevated PSA | No focus of tumour | 11.4 | Biopsy not performed |
| 61 | 12 mo after | Lung nodule | 5.2 | Elevated PSA, positive family history | No focus of tumour | 4.5 | Biopsy not performed |
| 68 | 7 mo after | Colorectal cancer | 8.8 | Incidental prostatic 18F-FDG uptake | No focus of tumour | 3 | Biopsy not performed |
SUV: Standardised uptake value, PSA: Prostate specific antigen, TRUS: Transrectal ultrasound.